Patrick H Maxwell

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2556522/publications.pdf

Version: 2024-02-01

212 papers

37,690 citations

4960 84 h-index 2953 189 g-index

228 all docs

228 docs citations

times ranked

228

36242 citing authors

#	Article	IF	Citations
1	Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature, 2022, 603, 706-714.	27.8	756
2	Improving the efficiency and effectiveness of an industrial SARS-CoV-2 diagnostic facility. Scientific Reports, 2022, 12, 3114.	3.3	2
3	Rolling back human pluripotent stem cells to an eight-cell embryo-like stage. Nature, 2022, 605, 315-324.	27.8	87
4	Coagulation factor V is a T-cell inhibitor expressed by leukocytes in COVID-19. IScience, 2022, 25, 103971.	4.1	7
5	The impact of hypoxia on B cells in COVID-19. EBioMedicine, 2022, 77, 103878.	6.1	15
6	Cell transcriptomic atlas of the non-human primate Macaca fascicularis. Nature, 2022, 604, 723-731.	27.8	81
7	Spatiotemporal transcriptomic atlas of mouse organogenesis using DNA nanoball-patterned arrays. Cell, 2022, 185, 1777-1792.e21.	28.9	437
8	Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection. ELife, 2021, 10, .	6.0	57
9	Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature, 2021, 596, 417-422.	27.8	549
10	The HIF complex recruits the histone methyltransferase SET1B to activate specific hypoxia-inducible genes. Nature Genetics, 2021, 53, 1022-1035.	21.4	38
11	Hypoxia-inducible factor 2 inhibitors show promise in advanced kidney cancer. Nature Reviews Urology, 2021, 18, 516-517.	3.8	3
12	SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature, 2021, 599, 114-119.	27.8	1,041
13	Mass testing of university students for covid-19. BMJ, The, 2021, 375, n2388.	6.0	10
14	Dynamic regulation of hypoxia-inducible factor- \hat{l} ± activity is essential for normal B cell development. Nature Immunology, 2020, 21, 1408-1420.	14.5	40
15	Mannose Binding Lectin Is Hydroxylated by Collagen Prolyl-4-hydroxylase and Inhibited by Some PHD Inhibitors. Kidney360, 2020, 1, 447-457.	2.1	4
16	Independence of HIF1a and androgen signaling pathways in prostate cancer. BMC Cancer, 2020, 20, 469.	2.6	25
17	A new approach to treating renal anaemia. Nature Reviews Nephrology, 2019, 15, 731-732.	9.6	9
18	HIF-1α metabolically controls collagen synthesis and modification in chondrocytes. Nature, 2019, 565, 511-515.	27.8	169

#	Article	IF	CITATIONS
19	VHL-Mediated Regulation of CHCHD4 and Mitochondrial Function. Frontiers in Oncology, 2018, 8, 388.	2.8	23
20	EP-2298: Hypoxia inducible factor $1\hat{l}\pm$ confers androgen independence in prostate cancer. Radiotherapy and Oncology, 2018, 127, S1268.	0.6	0
21	Osteocytic oxygen sensing controls bone mass through epigenetic regulation of sclerostin. Nature Communications, 2018, 9, 2557.	12.8	92
22	Single-cell transcriptomes from human kidneys reveal the cellular identity of renal tumors. Science, 2018, 361, 594-599.	12.6	511
23	Fumarylacetoacetate Hydrolase Knock-out Rabbit Model for Hereditary Tyrosinemia Type 1. Journal of Biological Chemistry, 2017, 292, 4755-4763.	3.4	15
24	Cardiopulmonary phenotype associated with humanPHD2mutation. Physiological Reports, 2017, 5, e13224.	1.7	10
25	Complement C1q is hydroxylated by collagen prolyl 4 hydroxylase and is sensitive to off-target inhibition by prolyl hydroxylase domain inhibitors that stabilize hypoxia-inducible factor. Kidney International, 2017, 92, 900-908.	5.2	18
26	Hypoxia and B cells. Experimental Cell Research, 2017, 356, 197-203.	2.6	36
27	Early loss of Crebbp confers malignant stem cell properties on lymphoid progenitors. Nature Cell Biology, 2017, 19, 1093-1104.	10.3	58
28	Homozygous p.Ser267Phe in SLC10A1 is associated with a new type of hypercholanemia and implications for personalized medicine. Scientific Reports, 2017, 7, 9214.	3.3	36
29	Mutations in mitochondrial DNA causing tubulointerstitial kidney disease. PLoS Genetics, 2017, 13, e1006620.	3.5	52
30	Prolyl hydroxylase 2 inactivation enhances glycogen storage and promotes excessive neutrophilic responses. Journal of Clinical Investigation, 2017, 127, 3407-3420.	8.2	71
31	A functional variant in NEPH3 gene confers high risk of renal failure in primary hematuric glomerulopathies. Evidence for predisposition to microalbuminuria in the general population. PLoS ONE, 2017, 12, e0174274.	2.5	20
32	Dent Disease in Chinese Children and Findings from Heterozygous Mothers: Phenotypic Heterogeneity, Fetal Growth, and 10 Novel Mutations. Journal of Pediatrics, 2016, 174, 204-210.e1.	1.8	13
33	Manifesto for a healthy and health-creating society. Lancet, The, 2016, 388, e24-e27.	13.7	11
34	Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition. Nature, 2016, 537, 544-547.	27.8	443
35	Hypoxia-induced nitric oxide production and tumour perfusion is inhibited by pegylated arginine deiminase (ADI-PEG20). Scientific Reports, 2016, 6, 22950.	3.3	32
36	A novel <i>COL4A1</i> frameshift mutation in familial kidney disease: the importance of the C-terminal NC1 domain of type IV collagen. Nephrology Dialysis Transplantation, 2016, 31, 1908-1914.	0.7	24

3

#	Article	IF	CITATIONS
37	HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond. Nature Reviews Nephrology, 2016, 12, 157-168.	9.6	234
38	$HIF-1\hat{l}\pm Promotes$ Glutamine-Mediated Redox Homeostasis and Glycogen-Dependent Bioenergetics to Support Postimplantation Bone Cell Survival. Cell Metabolism, 2016, 23, 265-279.	16.2	142
39	Tumor necrosis factor receptor 2-signaling in CD133-expressing cells in renal clear cell carcinoma. Oncotarget, 2016, 7, 24111-24124.	1.8	16
40	SP014A NOVEL COL4A1 FRAMESHIFT MUTATION AND KIDNEY DISEASE WITHOUT EXTRA-RENAL INVOLVEMENT IN A LARGE TURKISH CYPRIOT FAMILY. Nephrology Dialysis Transplantation, 2015, 30, iii385-iii385.	0.7	0
41	Combinatorial Conflicting Homozygosity (CCH) analysis enables the rapid identification of shared genomic regions in the presence of multiple phenocopies. BMC Genomics, 2015, 16, 163.	2.8	5
42	Autosomal dominant polycystic kidney disease: the changing face of clinical management. Lancet, The, 2015, 385, 1993-2002.	13.7	227
43	Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease. Kidney International, 2014, 86, 1244-1252.	5.2	91
44	Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survivalan analysis of data from the ERA-EDTA Registry. Nephrology Dialysis Transplantation, 2014, 29, iv15-iv25.	0.7	180
45	Loss of PHD3 allows tumours to overcome hypoxic growth inhibition and sustain proliferation through EGFR. Nature Communications, 2014, 5, 5582.	12.8	61
46	The Hypoxia-inducible Factor Renders Cancer Cells More Sensitive to Vitamin C-induced Toxicity. Journal of Biological Chemistry, 2014, 289, 3339-3351.	3.4	45
47	HIF-1 reduces ischaemia–reperfusion injury in the heart by targeting the mitochondrial permeability transition pore. Cardiovascular Research, 2014, 104, 24-36.	3.8	136
48	Rare inherited kidney diseases: challenges, opportunities, and perspectives. Lancet, The, 2014, 383, 1844-1859.	13.7	194
49	Renal cell carcinoma: translational aspects of metabolism and therapeutic consequences. Kidney International, 2013, 84, 667-681.	5.2	28
50	C3 glomerulonephritis and CFHR5 nephropathy. Nephrology Dialysis Transplantation, 2013, 28, 282-288.	0.7	22
51	Cezanne Regulates Inflammatory Responses to Hypoxia in Endothelial Cells by Targeting TRAF6 for Deubiquitination. Circulation Research, 2013, 112, 1583-1591.	4.5	51
52	The hypoxia factor Hif- $1\hat{l}_{\pm}$ controls neural crest chemotaxis and epithelial to mesenchymal transition. Journal of Cell Biology, 2013, 201, 759-776.	5.2	119
53	Incidence of End-Stage Renal Disease in the Turkish-Cypriot Population of Northern Cyprus: A Population Based Study. PLoS ONE, 2013, 8, e54394.	2.5	12
54	Epistatic Role of the MYH9/APOL1 Region on Familial Hematuria Genes. PLoS ONE, 2013, 8, e57925.	2.5	11

#	Article	IF	CITATIONS
55	Increasing evidence that genetic variation in Complement factor H related 5 (CFHR5) causes disease: A commentary on  Atypical haemolytic uremic syndrome and genetic aberrations in the complement factor-H-related 5 gene'. Journal of Human Genetics, 2012, 57, 473-474.	2.3	0
56	Von Hippel-Lindau protein in the RPE is essential for normal ocular growth and vascular development. Development (Cambridge), 2012, 139, 2340-2350.	2.5	23
57	What happens to clinical training fellows? A retrospective study of the 20â€years outcome of a Medical Research Council UK cohort. BMJ Open, 2012, 2, e001792.	1.9	8
58	The ERA-EDTA Working Group on inherited kidney disorders. Nephrology Dialysis Transplantation, 2012, 27, 67-69.	0.7	10
59	Endogenous Erythropoietin Protects Neuroretinal Function in Ischemic Retinopathy. American Journal of Pathology, 2012, 180, 1726-1739.	3.8	33
60	Tumor strengths and frailties: Aspiring to prevent colon cancer. Nature Medicine, 2012, 18, 32-33.	30.7	7
61	Renal Tubular HIF-2α Expression Requires VHL Inactivation and Causes Fibrosis and Cysts. PLoS ONE, 2012, 7, e31034.	2.5	78
62	Human CHCHD4 mitochondrial proteins regulate cellular oxygen consumption rate and metabolism and provide a critical role in hypoxia signaling and tumor progression. Journal of Clinical Investigation, 2012, 122, 600-611.	8.2	82
63	Macrophage skewing by Phd2 haplodeficiency prevents ischaemia by inducing arteriogenesis. Nature, 2011, 479, 122-126.	27.8	265
64	Prolyl Hydroxylase Phd3 Is Essential For Hypoxic Regulation Of Neutrophilic Inflammation., 2011,,.		0
65	Dysregulation of the HIF pathway due to VHL mutation causing severe erythrocytosis and pulmonary arterial hypertension. Blood, 2011, 117, 3699-3701.	1.4	41
66	Renal Cyst Formation in Fh1-Deficient Mice Is Independent of the Hif/Phd Pathway: Roles for Fumarate in KEAP1 Succination and Nrf2 Signaling. Cancer Cell, 2011, 20, 524-537.	16.8	494
67	Inactivation of the von Hippel-Lindau tumour suppressor gene induces Neuromedin U expression in renal cancer cells. Molecular Cancer, 2011, 10, 89.	19.2	26
68	Seeing the smoking gun: a sensitive and specific method to visualize loss of the tumour suppressor, fumarate hydratase, in human tissues. Journal of Pathology, 2011, 225, 1-3.	4.5	12
69	Copy number profiling in von hippelâ€lindau disease renal cell carcinoma. Genes Chromosomes and Cancer, 2011, 50, 479-488.	2.8	17
70	Dimethyloxalyglycine stimulates the early stages of gastrointestinal repair processes through VEGF-dependent mechanisms. Laboratory Investigation, 2011, 91, 1684-1694.	3.7	20
71	Hypoxia-Inducible Transcription Factors Stabilization in the Thick Ascending Limb Protects against Ischemic Acute Kidney Injury. Journal of the American Society of Nephrology: JASN, 2011, 22, 2004-2015.	6.1	88
72	Familial C3 Glomerulopathy Associated with CFHR5 Mutations. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1436-1446.	4.5	124

#	Article	IF	CITATIONS
73	Cardiopulmonary function in two human disorders of the hypoxiaâ€inducible factor (HIF) pathway: von Hippelâ€Lindau disease and HIFâ€2α gainâ€ofâ€function mutation. FASEB Journal, 2011, 25, 2001-2011.	0.5	86
74	Microchimeric Fetal Cells Are Recruited to Maternal Kidney following Injury and Activate Collagen Type I Transcription. Cells Tissues Organs, 2011, 193, 379-392.	2.3	15
75	Developmentally arrested structures preceding cerebellar tumors in von Hippel–Lindau disease. Modern Pathology, 2011, 24, 1023-1030.	5. 5	30
76	Prolyl hydroxylase 3 (PHD3) is essential for hypoxic regulation of neutrophilic inflammation in humans and mice. Journal of Clinical Investigation, 2011, 121, 1053-1063.	8.2	147
77	Genetic loci influencing kidney function and chronic kidney disease. Nature Genetics, 2010, 42, 373-375.	21.4	246
78	The hypoxia response pathway and <i>β</i> à€ell function. Diabetes, Obesity and Metabolism, 2010, 12, 159-167.	4.4	95
79	HIF-1alpha and HIF-2alpha Are Differentially Activated in Distinct Cell Populations in Retinal Ischaemia. PLoS ONE, 2010, 5, e11103.	2.5	90
80	Hypoxia and Upregulation of Hypoxia-Inducible Factor $1\hat{l}\pm$ Stimulate Venous Thrombus Recanalization. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 2443-2451.	2.4	56
81	VHL Inactivation Induces HEF1 and Aurora Kinase A. Journal of the American Society of Nephrology: JASN, 2010, 21, 2041-2046.	6.1	60
82	HLA Has Strongest Association with IgA Nephropathy in Genome-Wide Analysis. Journal of the American Society of Nephrology: JASN, 2010, 21, 1791-1797.	6.1	233
83	Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin. Haematologica, 2010, 95, 505-508.	3.5	159
84	Variation in IGHMBP2 is not associated with IgA nephropathy in independent studies of UK Caucasian and Chinese Han patients. Nephrology Dialysis Transplantation, 2010, 25, 1547-1554.	0.7	5
85	Variation in IGHMBP2 is not associated with IgA nephropathy in independent studies of UK Caucasian and Chinese Han patients. Nephrology Dialysis Transplantation, 2010, 25, 1-1.	0.7	0
86	Expression Profiling in Progressive Stages of Fumarate-Hydratase Deficiency: The Contribution of Metabolic Changes to Tumorigenesis. Cancer Research, 2010, 70, 9153-9165.	0.9	63
87	Prolyl Hydroxylase Domain Inhibitors: A Route to HIF Activation and Neuroprotection. Antioxidants and Redox Signaling, 2010, 12, 459-480.	5.4	92
88	Loss or Silencing of the PHD1 Prolyl Hydroxylase Protects Livers of Mice Against Ischemia/Reperfusion Injury. Gastroenterology, 2010, 138, 1143-1154.e2.	1.3	108
89	Loss of Prolyl Hydroxylase-1 Protects Against Colitis Through Reduced Epithelial Cell Apoptosis and Increased Barrier Function. Gastroenterology, 2010, 139, 2093-2101.	1.3	175
90	The role of HIF in immunity. International Journal of Biochemistry and Cell Biology, 2010, 42, 486-494.	2.8	30

#	Article	IF	Citations
91	Further Pharmacological and Genetic Evidence for the Efficacy of PIGF Inhibition in Cancer and Eye Disease. Cell, 2010, 141, 178-190.	28.9	243
92	Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet, The, 2010, 376, 794-801.	13.7	298
93	Differentiation in Neuroblastoma: Diffusion-Limited Hypoxia Induces Neuro-Endocrine Secretory Protein 55 and Other Markers of a Chromaffin Phenotype. PLoS ONE, 2010, 5, e12825.	2.5	10
94	The Molecular Genetics and Pathology of Renal Cell Carcinoma. , 2010, , 360-373.		0
95	Evidence for a Lack of a Direct Transcriptional Suppression of the Iron Regulatory Peptide Hepcidin by Hypoxia-Inducible Factors. PLoS ONE, 2009, 4, e7875.	2.5	76
96	Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney International, 2009, 75, 976-981.	5.2	266
97	Oxygen availability sHIFts the cell cycle. Cell Cycle, 2009, 8, 1305-1307.	2.6	0
98	Xenon Preconditioning Protects against Renal Ischemic-Reperfusion Injury via HIF-1α Activation. Journal of the American Society of Nephrology: JASN, 2009, 20, 713-720.	6.1	198
99	Regulation of Renal Epithelial Tight Junctions by the von Hippel-Lindau Tumor Suppressor Gene Involves Occludin and Claudin 1 and Is Independent of E-Cadherin. Molecular Biology of the Cell, 2009, 20, 1089-1101.	2.1	70
100	Novel insights into the role of the tumor suppressor von Hippel Lindau in cellular differentiation, ciliary biology, and cyst repression. Journal of Molecular Medicine, 2009, 87, 871-877.	3.9	15
101	Genome-wide association study identifies variants in TMPRSS6 associated with hemoglobin levels. Nature Genetics, 2009, 41, 1170-1172.	21.4	217
102	Identification of novel VHL regulated genes by transcriptomic analysis of RCC10 renal carcinoma cells. Advances in Enzyme Regulation, 2009, 49, 43-52.	2.6	6
103	Heterozygous Deficiency of PHD2 Restores Tumor Oxygenation and Inhibits Metastasis via Endothelial Normalization. Cell, 2009, 136, 839-851.	28.9	727
104	A mutant complement factor H-related 5 protein is associated with familial C3 glomerulonephritis. Molecular Immunology, 2009, 46, 2822.	2.2	2
105	Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies. Journal of Enzyme Inhibition and Medicinal Chemistry, 2009, 24, 1-39.	5.2	167
106	PTEN CAN FUNCTION AS A TUMOR SUPPRESSOR IN CLEAR CELL RENAL CARCINOMA. Journal of Urology, 2009, 181, 35-36.	0.4	97
107	Response to â€ [*] Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease'. Kidney International, 2009, 76, 1116.	5.2	1
108	Response to †Hepcidin levels in patients with renal disease'. Kidney International, 2009, 76, 680-681.	5.2	1

#	Article	IF	CITATIONS
109	Response to â€The utility of multivariate analysis in the study of hepcidin'. Kidney International, 2009, 76, 912-913.	5.2	1
110	Variations within oxygen-regulated gene expression in humans. Journal of Applied Physiology, 2009, 106, 212-220.	2.5	37
111	A report of succinate dehydrogenase B deficiency associated with metastatic papillary renal cell carcinoma: successful treatment with the multi-targeted tyrosine kinase inhibitor sunitinib. BMJ Case Reports, 2009, 2009, bcr0820080732-bcr0820080732.	0.5	13
112	Deletion of the von Hippelâ \in "Lindau gene in pancreatic \hat{l}^2 cells impairs glucose homeostasis in mice. Journal of Clinical Investigation, 2009, 119, 125-35.	8.2	108
113	Genetic Contribution to IgA Nephropathy. , 2009, , 21-36.		O
114	The A20 gene protects kidneys from ischaemia/reperfusion injury by suppressing pro-inflammatory activation. Journal of Molecular Medicine, 2008, 86, 1329-1339.	3.9	43
115	Inhibition of Hypoxia Inducible Factor Hydroxylases Protects Against Renal Ischemia-Reperfusion Injury. Journal of the American Society of Nephrology: JASN, 2008, 19, 39-46.	6.1	246
116	Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nature Genetics, 2008, 40, 170-180.	21.4	433
117	INACTIVATION OF THE PHOSPHATASE AND TENSIN HOMOLOG (PTEN) TUMOR SUPPRESSOR CONTRIBUTES TO TUMOR CHARACTERISTICS OF 786-O CLEAR CELL RENAL CARCINOMA CELLS. Journal of Urology, 2008, 179, 89-89.	0.4	O
118	Progression of Epididymal Maldevelopment Into Hamartoma-like Neoplasia in VHL Disease. Neoplasia, 2008, 10, 1146-1153.	5.3	26
119	The von Hippel-Lindau Tumor Suppressor Protein and Egl-9-Type Proline Hydroxylases Regulate the Large Subunit of RNA Polymerase II in Response to Oxidative Stress. Molecular and Cellular Biology, 2008, 28, 2701-2717.	2.3	115
120	Dialysis Survivors: Clinical Status of Patients on Treatment for More than 10 Years. Nephron Clinical Practice, 2008, 108, c207-c212.	2.3	3
121	Abnormal Sympathoadrenal Development and Systemic Hypotension in <i>PHD3</i> ^{<i>â^'</i>/i>/sâ^' Mice. Molecular and Cellular Biology, 2008, 28, 3386-3400.}	2.3	176
122	Expression of Hypoxia-Inducible Factors in Normal Human Lung Development. Pediatric and Developmental Pathology, 2008, 11, 193-199.	1.0	44
123	End-stage renal failure associated with congenital deafness. CKJ: Clinical Kidney Journal, 2008, 1, 171-175.	2.9	3
124	Autosomal dominant erythrocytosis and pulmonary arterial hypertension associated with an activating HIF2α mutation. Blood, 2008, 112, 919-921.	1.4	143
125	Role of Gas6 in erythropoiesis and anemia in mice. Journal of Clinical Investigation, 2008, 118, 583-96.	8.2	84
126	Reactivation of Snail Genes in Renal Fibrosis and Carcinomas: A Process of Reversed Embryogenesis?. Cell Cycle, 2007, 6, 638-642.	2.6	45

#	Article	IF	Citations
127	Lack of endothelial cell survivin causes embryonic defects in angiogenesis, cardiogenesis, and neural tube closure. Blood, 2007, 109, 4742-4752.	1.4	71
128	Erythropoietin gene expression in renal carcinoma is considerably more frequent than paraneoplastic polycythemia. International Journal of Cancer, 2007, 121, 2434-2442.	5.1	34
129	Inadvertent postdialysis anticoagulation due to heparin line locks. Hemodialysis International, 2007, 11, 430-434.	0.9	34
130	Targeted Inactivation of Fh1 Causes Proliferative Renal Cyst Development and Activation of the Hypoxia Pathway. Cancer Cell, 2007, 11, 311-319.	16.8	158
131	Genetic insights into the hypoxia-inducible factor (HIF) pathway. Advances in Enzyme Regulation, 2007, 47, 288-306.	2.6	5
132	Statin-induced expression of CD59 on vascular endothelium in hypoxia: a potential mechanism for the anti-inflammatory actions of statins in rheumatoid arthritis. Arthritis Research and Therapy, 2006, 8, R130.	3.5	32
133	HIF prolyl hydroxylases in the rat; organ distribution and changes in expression following hypoxia and coronary artery ligation. Journal of Molecular and Cellular Cardiology, 2006, 41, 68-77.	1.9	96
134	Mutation of von Hippel–Lindau Tumour Suppressor and Human Cardiopulmonary Physiology. PLoS Medicine, 2006, 3, e290.	8.4	163
135	Venular basement membranes contain specific matrix protein low expression regions that act as exit points for emigrating neutrophils. Journal of Experimental Medicine, 2006, 203, 1519-1532.	8.5	338
136	Neutrophils from patients with heterozygous germline mutations in the von Hippel Lindau protein (pVHL) display delayed apoptosis and enhanced bacterial phagocytosis. Blood, 2006, 108, 3176-3178.	1.4	63
137	Epididymal cystadenomas and epithelial tumourlets: effects of VHL deficiency on the human epididymis. Journal of Pathology, 2006, 210, 32-41.	4.5	39
138	Evolution of VHL tumourigenesis in nerve root tissue. Journal of Pathology, 2006, 210, 374-382.	4.5	37
139	Correction of severe anaemia using immuno-regulated gene therapy is achieved by restoring the early erythroblast compartment. British Journal of Haematology, 2006, 132, 608-614.	2.5	2
140	Snail activation disrupts tissue homeostasis and induces fibrosis in the adult kidney. EMBO Journal, 2006, 25, 5603-5613.	7.8	294
141	Genetic and structural analyses suggest that a novel SPG3A mutation causes severe phenotypes of hereditary spastic paraplegia. Science Bulletin, 2006, 51, 2038-2040.	1.7	1
142	Association of MEGSIN 2093C–2180T haplotype at the 3′ untranslated region with disease severity and progression of IgA nephropathy. Nephrology Dialysis Transplantation, 2006, 21, 1570-1574.	0.7	13
143	Regulation of E-cadherin Expression by VHL and Hypoxia-Inducible Factor. Cancer Research, 2006, 66, 3567-3575.	0.9	248
144	Organ-Specific Collagen Expression: Implications for Renal Disease. Nephron Experimental Nephrology, 2006, 102, e71-e75.	2.2	38

#	Article	IF	Citations
145	Genetic Studies of IgA Nephropathy. Nephron Experimental Nephrology, 2006, 102, e76-e80.	2.2	9
146	Formation of Primary Cilia in the Renal Epithelium Is Regulated by the von Hippel-Lindau Tumor Suppressor Protein. Journal of the American Society of Nephrology: JASN, 2006, 17, 1801-1806.	6.1	148
147	A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 654-659.	7.1	292
148	374: The Identity of the Angiogenic Switch in Renal Cancer. Journal of Urology, 2006, 175, 122-123.	0.4	0
149	368: The Cell of Origin of Clear Cell Renal Carcinoma - Re-Visited. Journal of Urology, 2006, 175, 120-121.	0.4	0
150	Venular basement membranes contain specific matrix protein low expression regions that act as exit points for emigrating neutrophils. Journal of Cell Biology, 2006, 173, i11-i11.	5.2	0
151	HIF, a missing link between metabolism and cancer. Nature Medicine, 2005, 11, 1047-1048.	30.7	58
152	Hypoxiaâ€inducible factor as a physiological regulator. Experimental Physiology, 2005, 90, 791-797.	2.0	137
153	Genetic evidence for a tumor suppressor role of HIF-2α. Cancer Cell, 2005, 8, 131-141.	16.8	174
154	A common pathway for genetic events leading to pheochromocytoma. Cancer Cell, 2005, 8, 91-93.	16.8	30
155	Distinct novel mutations affecting the same base in the NIPA1 gene cause autosomal dominant hereditary spastic paraplegia in two Chinese families. Human Mutation, 2005, 25, 135-141.	2.5	57
156	Manipulation of oxygen tensions forin vitrocell culture using a hypoxic workstation. Expert Review of Proteomics, 2005, 2, 307-314.	3.0	6
157	Effects of VHL Deficiency on Endolymphatic Duct and Sac. Cancer Research, 2005, 65, 10847-10853.	0.9	39
158	Is it rejection? Be on the lookout for â€~decoys'. Nephrology Dialysis Transplantation, 2005, 20, 2002-2004.	0.7	0
159	Contrasting Properties of Hypoxia-Inducible Factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-Associated Renal Cell Carcinoma. Molecular and Cellular Biology, 2005, 25, 5675-5686.	2.3	847
160	Tumor Cell Plasticity in Ewing Sarcoma, an Alternative Circulatory System Stimulated by Hypoxia. Cancer Research, 2005, 65, 11520-11528.	0.9	187
161	The HIF pathway in cancer. Seminars in Cell and Developmental Biology, 2005, 16, 523-530.	5.0	162
162	622: Von Hippel-Lindau Inactivation Downregulates the Cell-Cell Adhesion Molecule E Cadherin in Renal Cancer Cells. Journal of Urology, 2005, 173, 170-170.	0.4	0

#	Article	IF	Citations
163	Persistent induction of HIFâ€1α and â€2α in cardiomyocytes and stromal cells of ischemic myocardium. FASEB Journal, 2004, 18, 1415-1417.	0.5	118
164	HIF-1, An Oxygen and Metal Responsive Transcription Factor. Cancer Biology and Therapy, 2004, 3, 29-35.	3.4	210
165	HIF-1's Relationship to Oxygen: Simple yet Sophisticated. Cell Cycle, 2004, 3, 151-154.	2.6	43
166	Family-Based Association Study Showing that Immunoglobulin A Nephropathy Is Associated with the Polymorphisms 2093C and 2180T in the 3' Untranslated Region of the Megsin Gene. Journal of the American Society of Nephrology: JASN, 2004, 15, 1739-1743.	6.1	45
167	Gene array of VHL mutation and hypoxia shows novel hypoxia-induced genes and that cyclin D1 is a VHL target gene. British Journal of Cancer, 2004, 90, 1235-1243.	6.4	89
168	The prolyl hydroxylase enzymes that act as oxygen sensors regulating destruction of hypoxia-inducible factor \hat{l}_{\pm} . Advances in Enzyme Regulation, 2004, 44, 75-92.	2.6	28
169	Critical Amplification by Gas6 of the Epo-Dependent Erythropoietic Response to Anemia: Novel Opportunities for Anemia Treatment Blood, 2004, 104, 459-459.	1.4	0
170	HIF-1's relationship to oxygen: simple yet sophisticated. Cell Cycle, 2004, 3, 156-9.	2.6	18
171	HIF and oxygen sensing; as important to life as the air we breathe?. Annals of Medicine, 2003, 35, 183-190.	3.8	58
172	HIF-1. Journal of the American Society of Nephrology: JASN, 2003, 14, 2712-2722.	6.1	120
173	Widespread, hypoxiaâ€inducible expression of HIFâ€2α in distinct cell populations of different organs. FASEB Journal, 2003, 17, 271-273.	0.5	640
174	Evidence for hypoxiaâ€induced neuronalâ€toâ€chromaffin metaplasia in neuroblastoma. FASEB Journal, 2003, 17, 598-609.	0.5	17
175	Heterozygous deficiency of hypoxia-inducible factor–2α protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia. Journal of Clinical Investigation, 2003, 111, 1519-1527.	8.2	267
176	Regulation of HIF-1 by Oxygen. , 2003, , 47-64.		2
177	Peptide blockade of HIFÂ degradation modulates cellular metabolism and angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 10423-10428.	7.1	101
178	Oxygen homeostasis and cancer: insights from a rare disease. Clinical Medicine, 2002, 2, 356-362.	1.9	21
179	Expression of Hypoxia-Inducible Factor-1α and -2α in Hypoxic and Ischemic Rat Kidneys. Journal of the American Society of Nephrology: JASN, 2002, 13, 1721-1732.	6.1	521
180	Long-term reversal of chronic anemia using a hypoxia-regulated erythropoietin gene therapy. Blood, 2002, 100, 2406-2413.	1.4	86

#	Article	IF	Citations
181	Oxygen sensors and angiogenesis. Seminars in Cell and Developmental Biology, 2002, 13, 29-37.	5.0	288
182	Regulation of the HIF pathway: enzymatic hydroxylation of a conserved prolyl residue in hypoxia-inducible factor alpha subunits governs capture by the pVHL E3 ubiquitin ligase complex. Advances in Enzyme Regulation, 2002, 42, 333-347.	2.6	15
183	HIF activation identifies early lesions in VHL kidneys. Cancer Cell, 2002, 1, 459-468.	16.8	456
184	The use of dioxygen by HIF prolyl hydroxylase (PHD1). Bioorganic and Medicinal Chemistry Letters, 2002, 12, 1547-1550.	2.2	97
185	Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL. Nature, 2002, 417, 975-978.	27.8	651
186	Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nature Genetics, 2002, 32, 614-621.	21.4	469
187	Delivery of erythropoietin by encapsulated myoblasts in a genetic model of severe anemia. Kidney International, 2002, 62, 1395-1401.	5.2	32
188	Hypoxia-induced, perinecrotic expression of endothelial Per-ARNT-Sim domain protein-1/hypoxia-inducible factor-2alpha correlates with tumor progression, vascularization, and focal macrophage infiltration in bladder cancer. Clinical Cancer Research, 2002, 8, 471-80.	7.0	70
189	Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Research, 2002, 62, 2957-61.	0.9	186
190	Hypoxia and oxidative stress in breast cancer Hypoxia signalling pathways. Breast Cancer Research, 2001, 3, 313-7.	5.0	30
191	Guiding hands of our teachers. Lancet, The, 2001, 357, 480.	13.7	2
192	Activation of the HIF pathway in cancer. Current Opinion in Genetics and Development, 2001, 11, 293-299.	3.3	363
193	C. elegans EGL-9 and Mammalian Homologs Define a Family of Dioxygenases that Regulate HIF by Prolyl Hydroxylation. Cell, 2001, 107, 43-54.	28.9	3,293
194	Independent function of two destruction domains in hypoxia-inducible factor- \hat{l}_{\pm} chains activated by prolyl hydroxylation. EMBO Journal, 2001, 20, 5197-5206.	7.8	945
195	The pVHL-associated SCF ubiquitin ligase complex: Molecular genetic analysis of elongin B and C, Rbx1 and HIF-1α in renal cell carcinoma. Oncogene, 2001, 20, 5067-5074.	5.9	141
196	Selection of Mutant CHO Cells with Constitutive Activation of the HIF System and Inactivation of the von Hippel-Lindau Tumor Suppressor. Journal of Biological Chemistry, 2001, 276, 44323-44330.	3.4	29
197	Hypoxia-inducible Factor-2α (HIF-2α) Is Involved in the Apoptotic Response to Hypoglycemia but Not to Hypoxia. Journal of Biological Chemistry, 2001, 276, 39192-39196.	3.4	96
198	Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Human Molecular Genetics, 2001, 10, 1029-1038.	2.9	343

#	Article	IF	Citations
199	The HIF Pathway: Implications for Patterns of Gene Expression in Cancer. Novartis Foundation Symposium, 2001, 240, 212-231.	1.1	44
200	Targeting tumors through the HIF system. Nature Medicine, 2000, 6, 1315-1316.	30.7	310
201	Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling. Oncogene, 2000, 19, 6297-6305.	5.9	245
202	Effects of desferrioxamine on serum erythropoietin and ventilatory sensitivity to hypoxia in humans. Journal of Applied Physiology, 2000, 89, 680-686.	2.5	63
203	Hypoxia Inducible Factor-α Binding and Ubiquitylation by the von Hippel-Lindau Tumor Suppressor Protein. Journal of Biological Chemistry, 2000, 275, 25733-25741.	3.4	945
204	The Expression and Distribution of the Hypoxia-Inducible Factors HIF-1α and HIF-2α in Normal Human Tissues, Cancers, and Tumor-Associated Macrophages. American Journal of Pathology, 2000, 157, 411-421.	3.8	1,191
205	The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature, 1999, 399, 271-275.	27.8	4,528
206	Role of HIF-1 \hat{l}_{\pm} in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature, 1998, 394, 485-490.	27.8	2,565
207	Selection and Analysis of a Mutant Cell Line Defective in the Hypoxia-inducible Factor-1 α-Subunit (HIF-1α). Journal of Biological Chemistry, 1998, 273, 8360-8368.	3.4	174
208	Regulation of expression of the erythropoietin gene. Current Opinion in Hematology, 1998, 5, 166-170.	2.5	12
209	The interstitial response to renal injury: Fibroblast–like cells show phenotypic changes and have reduced potential for erythropoietin gene expression. Kidney International, 1997, 52, 715-724.	5.2	70
210	Sites of erythropoietin production. Kidney International, 1997, 51, 393-401.	5. 2	86
211	Oxygen regulated gene expression: Erythropoietin as a model system. Kidney International, 1997, 51, 514-526.	5.2	42
212	Identification of the renal erythropoietin-producing cells using transgenic mice. Kidney International, 1993, 44, 1149-1162.	5. 2	341